Denali Therapeutics Net Income
| DNLI Stock | USD 19.18 0.51 2.59% |
As of the 12th of February 2026, Denali Therapeutics shows the Mean Deviation of 2.93, downside deviation of 3.32, and Coefficient Of Variation of 891.33. Denali Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Denali Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 2.8 K | Earnings Share (2.92) | Quarterly Revenue Growth (1.00) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -380.5 M | -361.5 M | |
| Net Loss | -293.4 M | -278.7 M | |
| Net Loss | -380.5 M | -361.5 M | |
| Net Loss | (2.31) | (2.43) | |
| Net Income Per E B T | 0.90 | 0.80 |
Denali | Net Income | Build AI portfolio with Denali Stock |
The Net Income trend for Denali Therapeutics offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Denali Therapeutics is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Denali Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Denali Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Denali Therapeutics financial statement analysis. It represents the amount of money remaining after all of Denali Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Denali Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Denali Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (422.77 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Denali Net Income Regression Statistics
| Arithmetic Mean | (139,106,977) | |
| Geometric Mean | 74,668,174 | |
| Coefficient Of Variation | (113.58) | |
| Mean Deviation | 135,341,267 | |
| Median | (86,652,000) | |
| Standard Deviation | 157,997,438 | |
| Sample Variance | 24963.2T | |
| Range | 493.9M | |
| R-Value | (0.80) | |
| Mean Square Error | 9515.4T | |
| R-Squared | 0.64 | |
| Significance | 0.0001 | |
| Slope | (25,082,233) | |
| Total Sum of Squares | 399411T |
Denali Net Income History
Other Fundumenentals of Denali Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Denali Therapeutics Net Income component correlations
Denali Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Denali Therapeutics is extremely important. It helps to project a fair market value of Denali Stock properly, considering its historical fundamentals such as Net Income. Since Denali Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Denali Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Denali Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Denali introduce new products? Factors like these will boost the valuation of Denali Therapeutics. Projected growth potential of Denali fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Denali Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Denali Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Denali Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Denali Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Denali Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Denali Therapeutics.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Denali Therapeutics on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Denali Therapeutics or generate 0.0% return on investment in Denali Therapeutics over 90 days. Denali Therapeutics is related to or competes with Arcus Biosciences, Agios Pharm, Immunitybio, Beam Therapeutics, Recursion Pharmaceuticals, Cogent Biosciences, and Galapagos. Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerati... More
Denali Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Denali Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Denali Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.32 | |||
| Information Ratio | 0.092 | |||
| Maximum Drawdown | 23.32 | |||
| Value At Risk | (4.89) | |||
| Potential Upside | 6.5 |
Denali Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Denali Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Denali Therapeutics' standard deviation. In reality, there are many statistical measures that can use Denali Therapeutics historical prices to predict the future Denali Therapeutics' volatility.| Risk Adjusted Performance | 0.0991 | |||
| Jensen Alpha | 0.2983 | |||
| Total Risk Alpha | 0.0903 | |||
| Sortino Ratio | 0.1108 | |||
| Treynor Ratio | 0.2212 |
Denali Therapeutics February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0991 | |||
| Market Risk Adjusted Performance | 0.2312 | |||
| Mean Deviation | 2.93 | |||
| Semi Deviation | 3.1 | |||
| Downside Deviation | 3.32 | |||
| Coefficient Of Variation | 891.33 | |||
| Standard Deviation | 4.0 | |||
| Variance | 15.98 | |||
| Information Ratio | 0.092 | |||
| Jensen Alpha | 0.2983 | |||
| Total Risk Alpha | 0.0903 | |||
| Sortino Ratio | 0.1108 | |||
| Treynor Ratio | 0.2212 | |||
| Maximum Drawdown | 23.32 | |||
| Value At Risk | (4.89) | |||
| Potential Upside | 6.5 | |||
| Downside Variance | 11.01 | |||
| Semi Variance | 9.61 | |||
| Expected Short fall | (3.45) | |||
| Skewness | 0.5899 | |||
| Kurtosis | 1.78 |
Denali Therapeutics Backtested Returns
Denali Therapeutics appears to be not too volatile, given 3 months investment horizon. Denali Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0596, which denotes the company had a 0.0596 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Denali Therapeutics, which you can use to evaluate the volatility of the firm. Please utilize Denali Therapeutics' Coefficient Of Variation of 891.33, downside deviation of 3.32, and Mean Deviation of 2.93 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Denali Therapeutics holds a performance score of 4. The firm shows a Beta (market volatility) of 1.98, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Denali Therapeutics will likely underperform. Please check Denali Therapeutics' sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to make a quick decision on whether Denali Therapeutics' price patterns will revert.
Auto-correlation | -0.38 |
Poor reverse predictability
Denali Therapeutics has poor reverse predictability. Overlapping area represents the amount of predictability between Denali Therapeutics time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Denali Therapeutics price movement. The serial correlation of -0.38 indicates that just about 38.0% of current Denali Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.38 | |
| Spearman Rank Test | -0.49 | |
| Residual Average | 0.0 | |
| Price Variance | 4.08 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Denali Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Denali Therapeutics reported net income of (422.77 Million). This is 223.88% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 174.04% higher than that of the company.
Denali Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Denali Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Denali Therapeutics could also be used in its relative valuation, which is a method of valuing Denali Therapeutics by comparing valuation metrics of similar companies.Denali Therapeutics is currently under evaluation in net income category among its peers.
Denali Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Denali Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Denali Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Denali Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Denali Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Denali Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Denali Therapeutics' value.| Shares | Crestline Management Lp | 2025-06-30 | 3.9 M | Baker Bros Advisors Lp | 2025-06-30 | 3.7 M | T. Rowe Price Investment Management,inc. | 2025-06-30 | 3.2 M | Geode Capital Management, Llc | 2025-06-30 | 3.2 M | Alliancebernstein L.p. | 2025-06-30 | 3.1 M | Dimensional Fund Advisors, Inc. | 2025-06-30 | 2.4 M | Point72 Asset Management, L.p. | 2025-06-30 | 2.2 M | Goldman Sachs Group Inc | 2025-06-30 | 1.9 M | Fisher Asset Management, Llc | 2025-06-30 | 1.5 M | Blackrock Inc | 2025-06-30 | 12.1 M | Baillie Gifford & Co Limited. | 2025-06-30 | 12 M |
Denali Fundamentals
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 2.19 B | ||||
| Shares Outstanding | 156.16 M | ||||
| Shares Owned By Insiders | 9.28 % | ||||
| Shares Owned By Institutions | 97.28 % | ||||
| Number Of Shares Shorted | 13.56 M | ||||
| Price To Earning | 60.91 X | ||||
| Price To Book | 3.32 X | ||||
| Price To Sales | 3,644 X | ||||
| Gross Profit | (420.66 M) | ||||
| EBITDA | (492.89 M) | ||||
| Net Income | (422.77 M) | ||||
| Cash And Equivalents | 1.07 B | ||||
| Cash Per Share | 8.66 X | ||||
| Total Debt | 48.71 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 3.20 X | ||||
| Book Value Per Share | 6.32 X | ||||
| Cash Flow From Operations | (347.69 M) | ||||
| Short Ratio | 7.99 X | ||||
| Earnings Per Share | (2.92) X | ||||
| Target Price | 32.86 | ||||
| Number Of Employees | 517 | ||||
| Beta | 1.02 | ||||
| Market Capitalization | 3 B | ||||
| Total Asset | 1.37 B | ||||
| Retained Earnings | (1.54 B) | ||||
| Working Capital | 762.23 M | ||||
| Current Asset | 281.74 M | ||||
| Current Liabilities | 10.46 M | ||||
| Net Asset | 1.37 B |
About Denali Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Denali Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Denali Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Denali Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is there potential for Biotechnology market expansion? Will Denali introduce new products? Factors like these will boost the valuation of Denali Therapeutics. Projected growth potential of Denali fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Denali Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Denali Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Denali Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.